Keyhole limpet hemocyanin
- Generic Name
- Keyhole limpet hemocyanin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FV4Y0JO2CX
- Background
Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins.
- Indication
Investigated for use/treatment in bladder cancer and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT02079480
- Locations
- 🇺🇸
Parexel Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States
🇺🇸California Clinical Trials Medical Group, Glendale, California, United States
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 127
- Registration Number
- NCT01498328
- Locations
- 🇺🇸
University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Piedmont Atlanta Hospital, Atlanta, Georgia, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 745
- Registration Number
- NCT01480479
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00923910
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Vaccine Therapy in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019097
- Locations
- 🇺🇸
Arkansas Cancer Research Center, Little Rock, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Medicine Branch, Bethesda, Maryland, United States
Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 5
- Registration Number
- NCT00001145
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.